SCHEMBL3095091

SCHEMBL3095091

CCOC(=O)CCN(C)C(=O)c1ccc(NC(c2cc(-c3ccccc3)oc2CS(C)(=O)=O)C2CCCCC2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.35
TSHR P16473 1/20 0.35
TDP1 Q9NUW8 2/20 0.34
MCHR1 Q99705 1/20 0.32
RCE1 Q9Y256 1/20 0.32
TEAD4 Q15561 1/20 0.32
SLC6A9 P48067 1/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
ALDH1A1 P00352 2/20 0.31
MAPT P10636 2/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
DGAT1 O75907 1/20 0.31
TRPV4 Q9HBA0 1/20 0.31
PGR P06401 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3109960 0.92 TEAD4 (0.35) L3MBTL1TDP1MCHR1RCE1TEAD4
SCHEMBL3089930 0.91 MCHR1 (0.34) MCHR1MAPTTRPV4GCG
SCHEMBL3094591 0.89 L3MBTL1 (0.34) L3MBTL1TSHRTDP1MCHR1RCE1
SCHEMBL3104278 0.88 L3MBTL1 (0.34) L3MBTL1TSHRTDP1MCHR1RCE1
SCHEMBL3106798 0.87 MEN1 (0.42) L3MBTL1TSHRTDP1MEN1KMT2A
SCHEMBL3106477 0.84 GLP1R (0.37) MCHR1MAPTTRPV4TP53GCG
SCHEMBL3110628 0.83 GCG (0.38) L3MBTL1TDP1MCHR1RCE1TEAD4
SCHEMBL3089995 0.83 MCHR1 (0.36) MCHR1MAPTTRPV4GCG
SCHEMBL3107473 0.82 MEN1 (0.37) L3MBTL1TDP1MCHR1MEN1KMT2A
SCHEMBL3095040 0.82 ALDH1A1 (0.36) L3MBTL1TDP1MCHR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2210876-B1 HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST TAKEDA PHARMACEUTICAL (JP) 2015-05-20 EP disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 US disclosed
EP-2210876-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256156-A1 HETEROCYCLIC COMPOUND GLP1R, GPR119, GCGR L3MBTL1 1084/4885TSHR 60/4885TDP1 4801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.